A double-blind, placebo-controlled evaluation of the safety and efficacy of RGH-188 [cariprazine] in the acute exacerbation of schizophrenia

Trial Profile

A double-blind, placebo-controlled evaluation of the safety and efficacy of RGH-188 [cariprazine] in the acute exacerbation of schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Cariprazine (Primary)
  • Indications Schizophrenia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 20 Sep 2016 Post hoc pooled analysis results of this (NCT00404573) and other trials (NCT01058096, NCT00694707, NCT00488618, NCT01104766, NCT01058668, NCT01104779) presented at the 29th Annual Congress of the European College of Neuropsychopharmacology
    • 11 Dec 2015 Primary endpoint of the mean change in PANSS total score from baseline to Week 6 has not been met, according to results published in the International Clinical Psychopharmacology.
    • 11 Dec 2015 Results published in the International Clinical Psychopharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top